Clinical experience of anticoagulation and antiplatelet therapy for staged hybrid coronary revascularization

王有余,杨小东,王晓民,许哲通,张鲁锋,万峰

DOI: https://doi.org/10.3969/j.issn.1672-5301.2018.05.019

2018-01-01

Abstract:Objective To investigate the safety and effectiveness of perioperative anticoagulation and antiplatelet therapy for staged hybrid coronary revascularization in patients with multivessel coronary artery stenosis.Methods From Dec 2015 to Aug 2016,20 patients with multi-vessel coronary artery disease underwent staged hybrid coronary revascularization,which combined of minimally invasive direct coronary artery bypass and percutaneous coronary intervention.Oral aspirin of 100 mg/day was given before surgery.Intro-operative administration of heparin (1-3 mg/kg) to maintain active coagulation time over 300 second was neutralized by procaine at a ratio of 1∶2.Postoperative oral Aspirin(100 mg/day) and Clopidogrel(75 mg/day) lasted for 5 days until percutaneous intervention of other coronary artery lesions.Thereafter Aspirin (100 mg/day) for lifetime and Clopidogrel (75 mg/day) for 1 year was given for antiplatelet therapy.Major adverse cardiac and cerebral vascular events in hospital and at 1 year follow up were collected.Results 20 patients underwent successful staged hybrid coronary revascularization.No major adverse cardiac and cerebral vascular events occur during hospitalization and follow up.No bleeding events occurred in all patients.Conclusion This perioperative anticoagulation and antiplatelet therapy for staged coronary revascularization is safe and effective.